Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders

Author(s): Roger Kalla, Michael Strupp*.

Journal Name: Current Neuropharmacology

Volume 17 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Cerebellar ataxia is a frequent and often disabling syndrome severely impairing motor functioning and quality of life. Patients suffer from reduced mobility, and restricted autonomy, experiencing an even lower quality of life than, e.g., stroke survivors. Aminopyridines have been demonstrated viable for the symptomatic treatment of certain forms of cerebellar ataxia. This article will give an outline of the present pharmacotherapy of different cerebellar disorders. As a current key-therapy for the treatment of downbeat nystagmus 4-aminopyridine (4-AP) is suggested for the treatment of downbeat nystagmus (5–10 mg Twice a day [TID]), a frequent type of persisting nystagmus, due to a compromise of the vestibulo-cerebellum. Studies with animals have demonstrated, that a nonselective blockage of voltage-gated potassium channels (mainly Kv1.5) increases Purkinje- cell (PC) excitability. In episodic ataxia type 2 (EA2), which is frequently caused by mutations of the PQ-calcium channel, the efficacy of 4-AP (5–10 mg TID) has been shown in a randomized controlled trial (RCT). 4-AP was well tolerated in the recommended dosages. 4-AP was also effective in elevating symptoms in cerebellar gait ataxia of different etiologies (2 case series).

A new treatment option for cerebellar disease is the amino-acid acetyl-DL-leucine, which has significantly improved cerebellar symptoms in three case series. There are on-going randomized controlled trials for cerebellar ataxia (acetyl-DL-leucine vs placebo; ALCAT), cerebellar gait disorders (SR-form of 4-AP vs placebo; FACEG) and EA2 (sustained-release/SR-form of 4-AP vs acetazolamide vs placebo; EAT2TREAT), which will provide new insights into the pharmacological treatment of cerebellar disorders.

Keywords: Cerebellar ataxia, central vestibular disorders, aminopyridines, 4-aminopyridine, episodic ataxia type 2, downbeat nystagmus, acetyl-DL-leucine.

[1]
Jacobi, H.; Bauer, P.; Giunti, P.; Labrum, R.; Sweeney, M.G.; Charles, P.; Dürr, A.; Marelli, C.; Globas, C.; Linnemann, C.; Schöls, L.; Rakowicz, M.; Rola, R.; Zdzienicka, E.; Schmitz-Hübsch, T.; Fancellu, R.; Mariotti, C.; Tomasello, C.; Baliko, L.; Melegh, B.; Filla, A.; Rinaldi, C.; van de Warrenburg, B.P.; Verstappen, C.C.; Szymanski, S.; Berciano, J.; Infante, J.; Timmann, D.; Boesch, S.; Hering, S.; Depondt, C.; Pandolfo, M.; Kang, J.S.; Ratzka, S.; Schulz, J.; Tezenas du Montcel, S.; Klockgether, T. In: Adam, M.P.; Ardinger, H.H.; Pagon, R.A.; Wallace, S.E.; Bean, L.J.H.; Stephens, K.; Amemiya, A. Eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1998, 28, 1993-2018. [updated 2018 Sep 27]. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology, 2011, 77(11), 1035-1041. [http://dx.doi.org/10.1212/WNL.0b013 e31822e7ca0]. [PMID: 21832228].
[2]
Tsuji, S.; Onodera, O.; Goto, J.; Nishizawa, M. Sporadic ataxias in Japan--a population-based epidemiological study. Cerebellum, 2008, 7(2), 189-197. [http://dx.doi.org/10.1007/s12311-008-0028-x]. [PMID: 18418674].
[3]
Erichsen, A.K.; Koht, J.; Stray-Pedersen, A.; Abdelnoor, M.; Tallaksen, C.M. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain, 2009, 132(Pt 6), 1577-1588. [http://dx.doi.org/10.1093/brain/awp056]. [PMID: 19339254].
[4]
Muzaimi, M.B.; Thomas, J.; Palmer-Smith, S.; Rosser, L.; Harper, P.S.; Wiles, C.M.; Ravine, D.; Robertson, N.P. Population based study of late onset cerebellar ataxia in south east Wales. J. Neurol. Neurosurg. Psychiatry, 2004, 75(8), 1129-1134. [http://dx.doi. org/10.1136/jnnp.2003.014662]. [PMID: 15258214].
[5]
López-Bastida, J.; Perestelo-Pérez, L.; Montón-Alvarez, F.
Serrano-Aguilar, P. Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. Mov. Disord., 2008, 23(2), 212-217. [http://dx.doi.org/10.1002/ mds.21798]. [PMID: 17999424].
[6]
Perlman, S.L. Symptomatic and disease-modifying therapy for the progressive ataxias. Neurologist, 2004, 10(5), 275-289. [http://dx. doi.org/10.1097/01.nrl.0000141651.35193.67]. [PMID: 15335445].
[7]
Schmitz-Hübsch, T.; Coudert, M.; Giunti, P.; Globas, C.; Baliko, L.; Fancellu, R.; Mariotti, C.; Filla, A.; Rakowicz, M.; Charles, P.; Ribai, P.; Szymanski, S.; Infante, J.; van de Warrenburg, B.P.; Dürr, A.; Timmann, D.; Boesch, S.; Rola, R.; Depondt, C.; Schöls, L.; Zdzienicka, E.; Kang, J.S.; Ratzka, S.; Kremer, B.; Schulz, J.B.; Klopstock, T.; Melegh, B.; du Montcel, S.T.; Klockgether, T. Self-rated health status in spinocerebellar ataxia-results from a European multicenter study. Mov. Disord., 2010, 25(5), 587-595. [http:// dx.doi.org/10.1002/mds.22740]. [PMID: 20175183].
[8]
Ilg, W.; Bastian, A.J.; Boesch, S.; Burciu, R.G.; Celnik, P.; Claaßen, J.; Feil, K.; Kalla, R.; Miyai, I.; Nachbauer, W.; Schöls, L.; Strupp, M.; Synofzik, M.; Teufel, J.; Timmann, D. Consensus paper: management of degenerative cerebellar disorders. Cerebellum, 2014, 13(2), 248-268. [http://dx.doi.org/10.1007/s12311-013-0531-6]. [PMID: 24222635].
[9]
Claassen, J.; Spiegel, R.; Kalla, R.; Faldon, M.; Kennard, C.; Danchaivijitr, C.; Bardins, S.; Rettinger, N.; Schneider, E.; Brandt, T.; Jahn, K.; Teufel, J.; Strupp, M.; Bronstein, A. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms. J. Neurol. Neurosurg. Psychiatry, 2013, 84(12), 1392-1399. [http://dx.doi.org/10.1136/jnnp-2012-304736]. [PMID: 23813743].
[10]
Strupp, M.; Thurtell, M.J.; Shaikh, A.G.; Brandt, T.; Zee, D.S.; Leigh, R.J. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J. Neurol., 2011, 258(7), 1207-1222. [http://dx.doi.org/10.1007/s00415-011-5999-8]. [PMID: 21461686].
[11]
Strupp, M.; Brandt, T. Pharmacological advances in the treatment of neuro-otological and eye movement disorders. Curr. Opin. Neurol., 2006, 19(1), 33-40. [http://dx.doi.org/10.1097/01.wco. 0000196156.00481.e1]. [PMID: 16415675].
[12]
Kalla, R.; Teufel, J.; Feil, K.; Muth, C.; Strupp, M. Update on the pharmacotherapy of cerebellar and central vestibular disorders. J. Neurol., 2016, 263(Suppl. 1), S24-S29. [http://dx.doi.org/10.1007/ s00415-015-7987-x]. [PMID: 27083881].
[13]
Mehta, A.R.; Kennard, C. The pharmacological treatment of acquired nystagmus. Pract. Neurol., 2012, 12(3), 147-153. [http://dx. doi.org/10.1136/practneurol-2011-000181]. [PMID: 22661344].
[14]
Hille, B. Channels of Excitable Membranes 3rd Ed; Sinauer: Sunderlang; , 2001.
[15]
Etzion, Y.; Grossman, Y. Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp. Brain Res., 2001, 139(4), 419-425. [http://dx.doi.org/10.1007/s002210100788]. [PMID: 11534865].
[16]
Yazdi, H.H.; Janahmadi, M.; Behzadi, G. The role of small-conductance Ca2+-activated K+ channels in the modulation of 4-aminopyridine-induced burst firing in rat cerebellar Purkinje cells. Brain Res., 2007, 1156, 59-66. [http://dx.doi.org/10.1016/ j.brainres.2007.04.031]. [PMID: 17493598].
[17]
Haghdoost-Yazdi, H.; Janahmadi, M.; Behzadi, G. Iberiotoxin-sensitive large conductance Ca2+-dependent K+ (BK) channels regulate the spike configuration in the burst firing of cerebellar Purkinje neurons. Brain Res., 2008, 1212, 1-8. [http://dx.doi.org/ 10.1016/j.brainres.2008.03.030]. [PMID: 18439989].
[18]
Shaikh, A.G.; Marti, S.; Tarnutzer, A.A.; Palla, A.; Crawford, T.O.; Zee, D.S.; Straumann, D. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia. J. Neurol., 2013, 260(11), 2728-2735. [http://dx.doi.org/10.1007/s00415-013-7046-4]. [PMID: 23884713].
[19]
Hayes, K.C.; Katz, M.A.; Devane, J.G.; Hsieh, J.T.; Wolfe, D.L.; Potter, P.J.; Blight, A.R. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J. Clin. Pharmacol., 2003, 43(4), 379-385. [http://dx.doi.org/10.1177/0091270003251388]. [PMID: 12723458].
[20]
Alviña, K.; Khodakhah, K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J. Neurosci., 2010, 30(21), 7258-7268. [http://dx.doi.org/10.1523/JNEUROSCI.3582-09.2010]. [PMID: 20505092].
[21]
Weisz, C.J.; Raike, R.S.; Soria-Jasso, L.E.; Hess, E.J. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J. Neurosci., 2005, 25(16), 4141-4145. [http:// dx.doi.org/10.1523/JNEUROSCI.0098-05.2005]. [PMID: 15843617].
[22]
Wagner, J.N.; Glaser, M.; Brandt, T.; Strupp, M. Downbeat nystagmus: aetiology and comorbidity in 117 patients. J. Neurol. Neurosurg. Psychiatry, 2008, 79(6), 672-677. [http://dx.doi.org/ 10.1136/jnnp.2007.126284]. [PMID: 17872983].
[23]
Kalla, R.; Deutschlander, A.; Hüfner, K.; Stephan, T.; Jahn, K.; Glasauer, S.; Brandt, T.; Strupp, M. Detection of floccular hypometabolism in downbeat nystagmus by fMRI. Neurology, 2006, 66(2), 281-283. [http://dx.doi.org/10.1212/01.wnl.0000194242.28018.d9]. [PMID: 16434677].
[24]
Leigh, R.J.; Zee, D. The neurology of eye movements 4th Ed; Oxford University Press: Oxford, New York 2006.
[25]
Pierrot-Deseilligny, C.; Milea, D. Vertical nystagmus: clinical facts and hypotheses. Brain, 2005, 128(Pt 6), 1237-1246. [http:// dx.doi.org/10.1093/brain/awh532]. [PMID: 15872015].
[26]
Straumann, D.; Zee, D.S.; Solomon, D. Three-dimensional kinematics of ocular drift in humans with cerebellar atrophy. J. Neurophysiol., 2000, 83(3), 1125-1140. [http://dx.doi.org/10.1152/jn. 2000.83.3.1125]. [PMID: 10712443].
[27]
Strupp, M.; Schüler, O.; Krafczyk, S.; Jahn, K.; Schautzer, F.; Büttner, U.; Brandt, T. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology, 2003, 61(2), 165-170. [http://dx.doi.org/10.1212/01.WNL.0000078893. 41040.56]. [PMID: 12874393].
[28]
Kalla, R.; Glasauer, S.; Büttner, U.; Brandt, T.; Strupp, M. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain, 2007, 130(Pt 9), 2441-2451. [http://dx.doi.org/10.1093/brain/awm172]. [PMID: 17664175].
[29]
Kalla, R.; Spiegel, R.; Claassen, J.; Bardins, S.; Hahn, A.; Schneider, E.; Rettinger, N.; Glasauer, S.; Brandt, T.; Strupp, M. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus. J. Neuroophthalmol., 2011, 31(4), 320-325. [http://dx.doi.org/10.1097/ WNO.0b013e3182258086]. [PMID: 21734596].
[30]
Claassen, J.; Feil, K.; Bardins, S.; Teufel, J.; Spiegel, R.; Kalla, R.; Schneider, E.; Jahn, K.; Schniepp, R.; Strupp, M. Dalfampridine in patients with downbeat nystagmus--an observational study. J. Neurol., 2013, 260(8), 1992-1996. [http://dx.doi.org/10.1007/s00415-013-6911-5]. [PMID: 23589193].
[31]
Strupp, M.; Teufel, J.; Zwergal, A.; Schniepp, R.; Khodakhah, K.; Feil, K. Aminopyridines for the treatment of neurologic disorders. Neurol. Clin. Pract., 2017, 7(1), 65-76. [http://dx.doi.org/10.1212/ CPJ.0000000000000321]. [PMID: 28243504].
[32]
Ophoff, R.A.; Terwindt, G.M.; Vergouwe, M.N.; van Eijk, R.; Oefner, P.J.; Hoffman, S.M.; Lamerdin, J.E.; Mohrenweiser, H.W.; Bulman, D.E.; Ferrari, M.; Haan, J.; Lindhout, D.; van Ommen, G.J.; Hofker, M.H.; Ferrari, M.D.; Frants, R.R. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell, 1996, 87(3), 543-552. [http:// dx.doi.org/10.1016/S0092-8674(00)81373-2]. [PMID: 8898206].
[33]
Jen, J.; Kim, G.W.; Baloh, R.W. Clinical spectrum of episodic ataxia type 2. Neurology, 2004, 62(1), 17-22. [http://dx.doi. org/10.1212/01.WNL.0000101675.61074.50]. [PMID: 14718690].
[34]
Jen, J.C. Hereditary episodic ataxias. Ann. N. Y. Acad. Sci., 2008, 1142, 250-253. [http://dx.doi.org/10.1196/annals.1444.016]. [PMID: 18990130].
[35]
Jen, J.C.; Baloh, R.W. Familial episodic ataxia: a model for migrainous vertigo. Ann. N. Y. Acad. Sci., 2009, 1164, 252-256. [http:// dx.doi.org/10.1111/j.1749-6632.2008.03723.x]. [PMID: 19645908].
[36]
Neugebauer, H.; Adrion, C.; Glaser, M.; Strupp, M. Long-term changes of central ocular motor signs in patients with vestibular migraine. Eur. Neurol., 2013, 69(2), 102-107. [http://dx.doi.org/ 10.1159/000343814]. [PMID: 23182929].
[37]
Griggs, R.C.; Moxley, R.T., III; Lafrance, R.A.; McQuillen, J. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology, 1978, 28(12), 1259-1264. [http://dx.doi.org/10.1212/WNL. 28.12.1259]. [PMID: 366453].
[38]
Strupp, M.; Kalla, R.; Dichgans, M.; Freilinger, T.; Glasauer, S.; Brandt, T. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology, 2004, 62(9), 1623-1625. [http://dx.doi.org/10.1212/01.WNL.0000125691.74109.53]. [PMID: 15136697].
[39]
Strupp, M.; Kalla, R.; Claassen, J.; Adrion, C.; Mansmann, U.; Klopstock, T.; Freilinger, T.; Neugebauer, H.; Spiegel, R.; Dichgans, M.; Lehmann-Horn, F.; Jurkat-Rott, K.; Brandt, T.; Jen, J.C.; Jahn, K. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology, 2011, 77(3), 269-275. [http:// dx.doi.org/10.1212/WNL.0b013e318225ab07]. [PMID: 21734179].
[40]
Claassen, J.; Teufel, J.; Kalla, R.; Spiegel, R.; Strupp, M. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. J. Neurol., 2013, 260(2), 668-669. [http://dx. doi.org/10.1007/s00415-012-6764-3]. [PMID: 23183922].
[41]
Hourez, R.; Servais, L.; Orduz, D.; Gall, D.; Millard, I.; de Kerchove d’Exaerde, A.; Cheron, G.; Orr, H.T.; Pandolfo, M.; Schiffmann, S.N. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci., 2011, 31(33), 11795-11807. [http://dx.doi.org/ 10.1523/JNEUROSCI.0905-11.2011]. [PMID: 21849540].
[42]
Hourez, R.; Servais, L.; Orduz, D.; Gall, D.; Millard, I.; de Kerchove d’Exaerde, A.; Cheron, G.; Orr, H.T.; Pandolfo, M.; Schiffmann, S.N. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci., 2011, 31(33), 11795-11807. [http://dx.doi.org/ 10.1523/JNEUROSCI.0905-11.2011]. [PMID: 21849540].
[43]
Schniepp, R.; Wuehr, M.; Ackl, N.; Danek, A.; Brandt, T.; Strupp, M.; Jahn, K. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation. J. Neurol., 2011, 258(9), 1708-1711. [http://dx.doi.org/10.1007/s00415-011-5987-z]. [PMID: 21431381].
[44]
Schniepp, R.; Wuehr, M.; Neuhaeusser, M.; Benecke, A.K.; Adrion, C.; Brandt, T.; Strupp, M.; Jahn, K. 4-aminopyridine and cerebellar gait: a retrospective case series. J. Neurol., 2012, 259(11), 2491-2493. [http://dx.doi.org/10.1007/s00415-012-6595-2]. [PMID: 22760944].
[45]
Giordano, I.; Bogdanow, M.; Jacobi, H.; Jahn, K.; Minnerop, M.; Schoels, L.; Synofzik, M.; Teufel, J.; Klockgether, T. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia. J. Neurol., 2013, 260(8), 2175-2176. [http://dx.doi.org/10.1007/s00415-013-7029-5]. [PMID: 23824358].
[46]
Strupp, M.; Teufel, J.; Habs, M.; Feuerecker, R.; Muth, C.; van de Warrenburg, B.P.; Klopstock, T.; Feil, K. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J. Neurol., 2013, 260(10), 2556-2561. [http://dx.doi.org/10.1007/s00415-013-7016-x]. [PMID: 23835634].
[47]
Bremova, T.; Malinová, V.; Amraoui, Y.; Mengel, E.; Reinke, J.; Kolníková, M.; Strupp, M. Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology, 2015, 85(16), 1368-1375. [http://dx. doi.org/10.1212/WNL.0000000000002041]. [PMID: 26400580].
[48]
Schniepp, R.; Strupp, M.; Wuehr, M.; Jahn, K.; Dieterich, M.; Brandt, T.; Feil, K. Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series. Cerebellum Ataxias, 2016, 3, 8. [http://dx.doi.org/10.1186/s40673-016-0046-2]. [PMID: 27073690].
[49]
Highstein, S.M.; Holstein, G.R. The anatomy of the vestibular nuclei. Prog. Brain Res., 2006, 151, 157-203. [http://dx.doi.org/10. 1016/S0079-6123(05)51006-9] [PMID: 16221589]
[50]
Vibert, N.; Vidal, P.P. In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur. J. Neurosci., 2001, 13(4), 735-748. [http:// dx.doi.org/10.1046/j.0953-816x.2000.01447.x]. [PMID: 11207808].
[51]
Suh, B.C.; Hille, B. PIP2 is a necessary cofactor for ion channel function: how and why? Annu. Rev. Biophys., 2008, 37, 175-195. [http://dx.doi.org/10.1146/annurev.biophys.37.032807.125859]. [PMID: 18573078].
[52]
Witter, L.; Canto, C.B.; Hoogland, T.M.; de Gruijl, J.R.; De Zeeuw, C.I. Strength and timing of motor responses mediated by rebound firing in the cerebellar nuclei after Purkinje cell activation. Front. Neural Circuits, 2013, 7, 133. [http://dx.doi.org/10.3389/ fncir.2013.00133]. [PMID: 23970855].
[53]
Günther, L.; Beck, R.; Xiong, G.; Potschka, H.; Jahn, K.; Bartenstein, P.; Brandt, T.; Dutia, M.; Dieterich, M.; Strupp, M.; la Fougère, C.; Zwergal, A. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus. PLoS One, 2015, 10(3), e0120891. [http:// dx.doi.org/10.1371/journal.pone.0120891]. [PMID: 25803613].
[54]
Hull, J.; Hindy, M.E.; Kehoe, P.G.; Chalmers, K.; Love, S.; Conway, M.E. Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. J. Neurochem., 2012, 123(6), 997-1009. [http://dx.doi.org/10.1111/ jnc.12044]. [PMID: 23043456].
[55]
Sweatt, A.J.; Garcia-Espinosa, M.A.; Wallin, R.; Hutson, S.M. Branched-chain amino acids and neurotransmitter metabolism: expression of cytosolic branched-chain aminotransferase (BCATc) in the cerebellum and hippocampus. J. Comp. Neurol., 2004, 477(4), 360-370. [http://dx.doi.org/10.1002/cne.20200]. [PMID: 15329886].
[56]
Johnston, A.R.; Seckl, J.R.; Dutia, M.B. Role of the flocculus in mediating vestibular nucleus neuron plasticity during vestibular compensation in the rat. J. Physiol., 2002, 545(Pt 3), 903-911. [http://dx.doi.org/10.1113/jphysiol.2002.024281]. [PMID: 12482895].
[57]
Murai, N.; Tsuji, J.; Ito, J.; Mishina, M.; Hirano, T. Vestibular compensation in glutamate receptor delta-2 subunit knockout mice: dynamic property of vestibulo-ocular reflex. Eur. Arch. Otorhinolaryngol., 2004, 261, 82-86. [http://dx.doi.org/10.1007/s00405-003-0644-5].
[58]
Feil, K.; Adrion, C.; Teufel, J.; Bösch, S.; Claassen, J.; Giordano, I.; Hengel, H.; Jacobi, H.; Klockgether, T.; Klopstock, T.; Nachbauer, W.; Schöls, L.; Stendel, C.; Uslar, E.; van de Warrenburg, B.; Berger, I.; Naumann, I.; Bayer, O.; Müller, H.H.; Mansmann, U.; Strupp, M. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial. BMC Neurol., 2017, 17(1), 7. [http://dx.doi.org/10.1186/ s12883-016-0786-x]. [PMID: 28068987].


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 1
Year: 2019
Page: [7 - 13]
Pages: 7
DOI: 10.2174/1570159X16666180905093535
Price: $58

Article Metrics

PDF: 44
HTML: 6